Hikma Pharmaceuticals Plc Hikma completes acquisition of Teligent (5863A)
February 03 2022 - 1:59AM
UK Regulatory
TIDMHIK
RNS Number : 5863A
Hikma Pharmaceuticals Plc
03 February 2022
Hikma completes acquisition of Teligent sterile injectable
assets
London, 3 February 2022 - Hikma Pharmaceuticals PLC (Hikma), the
multinational pharmaceutical company, today announces that,
following its announcement on 17 January that it had agreed to
acquire the Canadian assets of Teligent Inc. for $45.75 million,
this transaction has now completed.
The acquisition marks Hikma's expansion into Canada and includes
a portfolio of 25 sterile injectable products, three in-licenced
ophthalmic products and a pipeline of seven additional products,
four of which are approved by Health Canada.
Riad Mishlawi, President of Hikma Injectables, commented, "The
completion of this acquisition expands Hikma's presence in the
highly attractive Canadian injectables market, bringing a strong
portfolio of sterile injectable products, as well as strengthening
our pipeline. We are excited to bring these important products to
our Canadian customers and their patients."
- ENDS -
Enquiries:
Hikma (Investors):
Susan Ringdal
EVP, Strategic Planning and Global +44 (0)20 7399 2760/ +44 (0)7776
Affairs 477050
Guy Featherstone +44 (0)20 3892 4389/ +44 (0)7795
Senior Investor Relations Manager 896738
Layan Kalisse +44 (0)20 7399 2788/ +44 (0)7970
Investor Relations Analyst 709912
Teneo (Press):
+44 (0)7703 330 269
Charles Armitstead
North America Media
Steven Weiss/David Belian +1 732 788 8279/ +1 848 254 4875
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable
S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for
millions of people around the world. For more than 40 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across the United States (US), the
Middle East and North Africa (MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,600 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACQTJMFTMTIMMJT
(END) Dow Jones Newswires
February 03, 2022 01:59 ET (06:59 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2024 to Jun 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2023 to Jun 2024